Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fostamatinib Disodium · Tavalisse, R935788

Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Rigel Pharms

Approved FDA, Apr 2018
RIGL Developer
5 Registered trials

What is Fostamatinib Disodium?

Fostamatinib disodium is an orally available prodrug of the SYK kinase inhibitor R406. It inhibits spleen tyrosine kinase, blocking Fc-gamma receptor and B-cell receptor signaling and reducing antibody-mediated destruction of platelets. It is studied in rheumatoid arthritis, idiopathic thrombocytopenic purpura and IgA nephropathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tavalisse, R935788, R788, Fostamatinib
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
Fc-gamma receptor signaling, B-cell receptor signaling
Therapy area
Hematology, Immunology
Developer
Rigel Pharms (RIGL)
FDA status
Approved as Tavalisse (April 17, 2018), NDA209299 · FDA label
UNII
86EEZ49YVB

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02077192 Phase 3 Immune Thrombocytopenic Purpura Completed RIGL
NCT02433236 Phase 2 IGA Nephropathy Withdrawn RIGL
NCT00665626 Phase 2 Rheumatoid Arthritis Completed RIGL
NCT00706342 Phase 2 Purpura, Thrombocytopenic, Idiopathic Completed RIGL
NCT03363334 N/A Immune Thrombocytopenic Purpura No longer available RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

IGA NephropathyImmune Thrombocytopenic PurpuraPurpura, Thrombocytopenic, IdiopathicRheumatoid Arthritis

Other drugs acting on SYK

More from Rigel Pharms

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind Fostamatinib Disodium

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.